Literature DB >> 18511472

Incretin levels in polycystic ovary syndrome.

Jana Vrbikova1, Martin Hill, Bela Bendlova, Tereza Grimmichova, Katerina Dvorakova, Karel Vondra, Giovanni Pacini.   

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) has been linked to a high risk of type 2 diabetes mellitus. Disturbances in the secretion of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) have been observed in states with impaired glucose regulation. This paper considers the secretion of GIP and GLP-1 after oral glucose load in a group of lean, glucose-tolerant PCOS women in comparison with age- and body mass index (BMI)-matched healthy women.
DESIGN: Case control.
METHODS: PCOS (n=21, 25.8+/-4.1 years, BMI 21.6+/-1.7 kg/m(2)) and control healthy women (CT, n=13, 28.5+/-7.2 years, BMI 20.3+/-2.5 kg/m(2)) underwent oral glucose tolerance test (OGTT) with blood sampling for glucose, insulin, C-peptide, total GIP, and active GLP-1. Insulin sensitivity was determined both at fasting and during the test. STATISTICS: Repeated measures ANOVA.
RESULTS: Glucose levels and insulin sensitivity did not differ between PCOS and CT. PCOS had significantly higher levels of C-peptide (P<0.05) and tended to have higher insulin levels. The levels of total GIP were significantly higher in PCOS than in CT (P<0.001). Active GLP-1 levels exhibited a significantly different time-dependent pattern in PCOS (P<0.002 for PCOS versus time interaction). GLP-1 concentrations were similar in PCOS and CT in the early phase of OGTT and then reached significantly lower levels in PCOS than in CT at 180 min (P<0.05).
CONCLUSIONS: Increased total GIP and lower late phase active GLP-1 concentrations during OGTT characterize PCOS women with higher C-peptide secretion in comparison with healthy controls, and may be the early markers of a pre-diabetic state.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511472     DOI: 10.1530/EJE-08-0097

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  23 in total

Review 1.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

Review 2.  Gastrointestinal hormones and polycystic ovary syndrome.

Authors:  Jing Ma; Tzu Chun Lin; Wei Liu
Journal:  Endocrine       Date:  2014-05-04       Impact factor: 3.633

Review 3.  Updates on molecular and environmental determinants of luteal progesterone production.

Authors:  Natalie A DeWitt; Shannon Whirledge; Amanda N Kallen
Journal:  Mol Cell Endocrinol       Date:  2020-06-28       Impact factor: 4.102

Review 4.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 5.  Neuroanatomical Framework of the Metabolic Control of Reproduction.

Authors:  Jennifer W Hill; Carol F Elias
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

6.  Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis.

Authors:  Yue Jin; Hong Liu; Shao-Gang Ma; Jian-Ping Cheng; Kai Zhang
Journal:  J Res Med Sci       Date:  2015-02       Impact factor: 1.852

7.  Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.

Authors:  Jessica K Devin; Hui Nian; Jorge E Celedonio; Patricia Wright; Nancy J Brown
Journal:  J Clin Endocrinol Metab       Date:  2020-01-01       Impact factor: 5.958

8.  Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS.

Authors:  Aesha Shah; William C Dodson; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Carol L Gnatuk; Stephanie J Estes; Kelly C Allison; David B Sarwer; Patrick M Sluss; Christos Coutifaris; Anuja Dokras; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

9.  Incretin Effect in Women with Former Gestational Diabetes within a Short Period after Delivery.

Authors:  G Pacini; A Tura; Y Winhofer; A Kautzky-Willer
Journal:  Int J Endocrinol       Date:  2012-04-19       Impact factor: 3.257

Review 10.  Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1.

Authors:  XingChun Wang; Huan Liu; Jiaqi Chen; Yan Li; Shen Qu
Journal:  Int J Endocrinol       Date:  2015-08-20       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.